K4 Elite logo K4 Elite
Home / Peptide Library / Selank
Emerging Research

Selank

Cognitive & Neurological · ['TP-7', 'Thr-Lys-Pro-Arg-Pro-Gly-Pro', 'Selank heptapeptide']

Selank is a synthetic heptapeptide derived from the immunomodulatory peptide tuftsin, studied in Russia for anxiolytic and neuropsychological research applications.

🔬 Research use only — not for human or veterinary use. K4 Elite does not provide dosing instructions.
Molecular Formula
C33H57N11O9
Molecular Weight
751.9 g/mol
PubChem
CID 11765600 ↗
Research Level
Emerging Research
Available in our store →
Selank chemical structure

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a stabilizing sequence (Pro-Gly-Pro) to increase resistance to enzymatic degradation.

Research on Selank, conducted primarily in Russia, has examined anxiolytic (anti-anxiety) activity, effects on learning and memory, and immunomodulatory properties. It has been described in the Russian literature as having been evaluated in clinical research for anxiety disorders.

Selank is not approved by the FDA or other Western regulatory agencies and remains an investigational compound outside of the Russian research context.

Proposed mechanisms from preclinical research include modulation of the GABAergic and serotonergic systems, effects on brain-derived neurotrophic factor (BDNF) expression, and influence on the metabolism of enkephalins by inhibiting their enzymatic breakdown, which may prolong their activity. Selank has also been reported to modulate the expression of genes related to inflammation and immune function.

These mechanisms are derived from animal studies and gene-expression research and have not been established through Western-standard controlled clinical trials.

  • Anxiolytic activity in rodent models of anxiety and stress [1]
  • Effects on learning, memory, and cognitive performance in animal models [2]
  • Modulation of BDNF and neurotrophic signaling in the brain [2]
  • Immunomodulatory activity related to its tuftsin-analogue origin [3]
  • Influence on enkephalin metabolism and monoamine systems [1]
📋 How published studies were conducted — a research reference summarizing study designs from the literature. This is not usage, dosing, or administration guidance. K4 Elite does not provide dosing instructions; determining any research protocol is the sole responsibility of the qualified researcher.

Kozlovskii and colleagues studied Selank in rodent behavioral models, reporting anxiolytic-like effects in tests such as the elevated plus maze, with time-in-open-arms and related behavioral indices as the measured outcomes [1].

Volkova and colleagues examined Selank in animal models and reported changes in BDNF expression in the hippocampus associated with the peptide, using gene- and protein-expression measures as endpoints [2].

Reviews of Selank's development summarize Russian clinical research in which the peptide was evaluated as an anxiolytic in generalized anxiety and related conditions, with clinical anxiety-rating outcomes reported in the source literature [3].

Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.

GABAergic systemSynergistic
Preclinical studies report anxiolytic effects associated with modulation of GABA signaling.
EnkephalinsSynergistic
Selank is reported to inhibit enkephalin degradation, potentially prolonging their activity in animal models.
BDNF / neurotrophic signalingSynergistic
Animal studies report modulation of BDNF expression in the brain.
BenzodiazepinesCaution
Both act on anxiety-related pathways; discussed comparatively in research literature, not as a co-administration recommendation.
SemaxCompatible
Another Russian-developed regulatory peptide studied in overlapping neuropsychological research contexts.
  1. Kozlovskii II et al., Eksp Klin Farmakol / behavioral studies (Selank anxiolytic)
  2. Volkova A et al., Front Pharmacol 2016 (Selank BDNF)
  3. Zozulya AA et al., Zh Nevrol Psikhiatr 2008 (Selank clinical anxiety)
  4. PubChem: Selank (CID 11765600)
What is Selank?
Selank is a synthetic seven-amino-acid peptide developed in Russia as an analogue of the natural peptide tuftsin. It has been studied mainly for anti-anxiety and cognitive research applications.
What research areas involve Selank?
Preclinical studies have examined anxiolytic activity, learning and memory, BDNF signaling, and immunomodulation, primarily in rodent models, along with Russian clinical research on anxiety.
Is Selank approved as a medicine?
It has been studied and used in a research and clinical context in Russia, but it is not approved by the FDA or other Western regulatory agencies.
How is Selank related to Semax?
Both are synthetic regulatory peptides developed in Russia and studied in overlapping neuropsychological research areas, though they have different sequences and proposed mechanisms.
Is this product intended for human use?
No. This material is supplied strictly for laboratory and research use only. It is not a drug or supplement and is not intended for human or veterinary consumption or administration.
Disclaimer: This profile summarizes published preclinical and laboratory research for reference only. It is not medical advice and makes no claim of safety or efficacy in humans. Determining any research protocol is the sole responsibility of the qualified researcher. Products are sold strictly for in-vitro research and have not been evaluated by the FDA.